Combination treatment of anti‐PD‐1 antibody with Lenvatinib already demonstrated enhanced anti‐cancer effect in a tumor model (Kato et al, 2019), as the latter selectively inhibits VEGFR1–3 and other proangiogenic and oncogenic pathway‐related receptor tyrosine kinases (RTKs), thus facilitating the traffic of immune T cells into the tumor microenvironment. Here, FLT1 is linked to neoplasm.